Screener
Eton Pharmaceuticals, Inc. ETON Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued Medicaid rebates | 11,140 | 9,317 |
| Accrued liabilities | 7,746 | 9,408 |
| Total current liabilities | 44,179 | 38,490 |
| Long-term debt, net of current portion and debt discount | 18,939 | 21,769 |
| Operating lease liabilities, net of current portion | 440 | 460 |
| Other long-term liabilities | 3,537 | 5,241 |
| Total liabilities | 67,095 | 65,960 |
| Commitments and contingencies (Note 13) |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s long-term debt?
- Eton Pharmaceuticals, Inc. (ETON) reported long-term debt of $18.94M in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Eton Pharmaceuticals, Inc.'s long-term debt decreased by 36.9% year-over-year, from $29.99M to $18.94M.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s long-term debt has grown at a 27.2% compound annual growth rate (CAGR), from $6.53M to $21.77M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Eton Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude